United Therapeutics (UTHR) Cost of Revenue (2009 - 2026)

United Therapeutics has disclosed Cost of Revenue across 18 years of filings, most recently posting $99.5 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 13.58% year-over-year to $99.5 million; the TTM figure through Jun 2026 stood at $437.2 million (up 28.93% YoY), while the FY2025 annual figure was $384.4 million, up 24.12% from the prior year.
• Cost of Revenue came in at $99.5 million for Q2 2026 at United Therapeutics, down from $133.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $133.4 million in Q1 2026 to a low of $25.9 million in Q1 2022.
• Average Cost of Revenue over 5 years is $74.2 million, with a median of $74.4 million recorded in 2024.
• Year-over-year, Cost of Revenue dropped 20.16% in 2022 and jumped 115.82% in 2023.
• Over 5 years, Cost of Revenue stood at $58.8 million in 2022, then rose by 20.75% to $71.0 million in 2023, then advanced by 6.9% to $75.9 million in 2024, then surged by 36.23% to $103.4 million in 2025, then declined by 3.77% to $99.5 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $99.5 million in Q2 2026, $133.4 million in Q1 2026, and $103.4 million in Q4 2025.